GlassScriptPhysician profile
Renee A Maloney
NPI 1720528631
$5,839.17
in general payments reported to CMS, 2019-2025
31 companies · $1,242 in 2025
The $1,242 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $174 · 2023: $1,602 · 2024: $2,820 · 2025: $1,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,425 · Long Term Medical Supply Or Device Loan: $2,180 · Consulting Fee: $648 · Education: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,425.37 |
| Long Term Medical Supply Or Device Loan | $2,179.99 |
| Consulting Fee | $647.50 |
| Education | $411.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,916.53 | 2023-2025 | Kisqali |
| Incyte Corporation | $305.37 | 2023-2024 | Jakafi, Pemazyre, Monjuvi |
| Abbvie INC. | $274.09 | 2024-2025 | |
| Seagen INC. | $258.66 | 2023 | Tukysa, Tivdak |
| Janssen Biotech, INC. | $231.08 | 2022-2024 | Erleada, Rybrevant, Akeega |
| Merck Sharp & Dohme LLC | $216.17 | 2023-2024 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $197.51 | 2023-2024 | Enhertu |
| Aveo Pharmaceuticals, INC. | $173.13 | 2023-2024 | Fotivda |
| Epizyme, INC. | $124.49 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $121.86 | 2023 | Imfinzi |
| Intera Oncology, INC | $114.21 | 2024 | Intera |
| Takeda Pharmaceuticals U.S.A., INC. | $95.20 | 2024 | Fruzaqla, Vpriv |
| Pfizer INC. | $94.04 | 2024 | |
| Glaxosmithkline, LLC. | $82.15 | 2022-2024 | Jemperli, Zejula |
| Gilead Sciences, INC. | $73.76 | 2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $60.24 | 2023-2024 | Reblozyl, Pomalyst |
| Lilly USA, LLC | $58.76 | 2024 | Verzenio, Jaypirca, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $48.09 | 2024 | Augtyro, Opdivo |
| Genentech USA, INC. | $47.03 | 2024-2025 | Itovebi, Venclexta |
| Astellas Pharma US INC | $45.41 | 2024 | Padcev, Xtandi |
| Stemline Therapeutics INC. | $39.91 | 2024 | Orserdu |
| Spectrum Pharmaceuticals INC. | $30.22 | 2023 | Rolvedon |
| Regeneron Healthcare Solutions, INC. | $29.65 | 2024 | Libtayo |
| Tempus Ai, INC | $29.23 | 2024 | |
| Sobi, INC | $27.57 | 2024 | |
| Eisai INC. | $27.12 | 2025 | |
| Beigene USA, INC. | $27.10 | 2025 | Tevimbra |
| Mirati Therapeutics, INC. | $26.87 | 2024 | Krazati |
| Coherus Oncology, INC. | $25.62 | 2024 | |
| Taiho Oncology, INC. | $22.61 | 2024 | |
| Acrotech Biopharma INC. | $15.49 | 2024 | Beleodaq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Maloney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.